GLP-1 Bone Density Loss: Do Semaglutide and Tirzepatide Weaken Bones?
GLP-1 Advisor › GLP-1 & Peptide Hub › Bone Density
By Dr. Frank Yap, MD, One Day Media Network · Medically reviewed by One Day MD Review Team · Published 2026-10-08 · Last updated 2026-10-08 · Reading time about 14 minutes
Quick Answer
Semaglutide and tirzepatide have not been proven to damage bone directly, but the large weight loss they produce is associated with measurable declines in hip and spine bone mineral density (BMD). Whether that raises fracture risk depends heavily on who you are.
- Type 2 diabetes: fracture risk appears similar or lower. A 44-trial meta-analysis found a pooled relative risk of 0.77, and a 2026 cohort study found a hazard ratio of 0.91.
- Obesity without diabetes: signals are less reassuring. The same 2026 cohort study found a hazard ratio of 1.13, and a small 52-week randomized trial found semaglutide left hip BMD about 2.6% lower than placebo.
- Tirzepatide: randomized bone-density data are lacking, and observational studies conflict.
- Highest attention: older adults, postmenopausal women, prior fragility fracture, long-term steroid use, low muscle mass, BMI 40 or higher, and rapid weight loss.
- What helps most: progressive strength and weight-bearing exercise, adequate protein, calcium and vitamin D sufficiency, steady (not extreme) weight loss, fall prevention, and a DXA scan when you meet standard screening criteria.
Evidence confidence: moderate for BMD decline tracking weight loss; low for fracture outcomes in non-diabetic users and for tirzepatide-specific effects.
In this guide
- Why weight loss affects bone
- BMD versus fracture: what actually matters
- What the studies show
- Why diabetes and non-diabetes results differ
- Semaglutide and bone
- Tirzepatide and bone
- Who is at higher risk
- How to protect your bones
- When to get a DXA scan
- What about stopping the drug?
- Evidence grading (CEBM)
- Frequently asked questions
- AI personalization guide
- Bottom line
- References
Why weight loss affects bone
Bone is a living tissue that responds to load. Substantial weight loss from any cause, including diet, bariatric surgery or medication, tends to increase bone turnover and lower bone mineral density, especially at the hip. In ordinary weight-loss studies, hip BMD often falls on the order of 1–2% in the first year of roughly 10% weight loss, though results vary.
.png)
Several mechanisms are thought to contribute:
- Less mechanical loading. A lighter body places less stress on the skeleton, which signals bone to remodel downward.
- Loss of muscle. Muscle and bone are linked mechanically and biochemically. The lean-mass changes discussed in our semaglutide versus tirzepatide muscle loss guide may therefore matter for bone too.
- Nutrition. Reduced appetite can lower intake of protein, calcium and vitamin D. See our GLP-1 nutrient deficiency protocol.
- Hormonal shifts. Fat tissue contributes to estrogen production after menopause, so large fat loss may change the hormonal environment for bone.
- Direct drug effects (uncertain). Bone cells carry receptors in this signaling family, and some animal and bone-turnover data suggest neutral or even favorable effects. Human relevance is unproven.
Evidence tier for the mechanisms above: CEBM Level 5 (mechanistic reasoning and preclinical data).
BMD versus fracture: what actually matters
Just as lean mass is not the same as muscle, bone density is not the same as bone strength. The clinically important outcome is a fracture, particularly of the hip or spine.
| Measure | What it tells you | Limitation |
|---|---|---|
| BMD (DXA) | Mineral per area at hip, spine or forearm | Does not capture bone architecture; large soft-tissue changes after major fat loss can influence readings |
| Bone turnover markers (CTX, P1NP) | Short-term resorption and formation activity | Early signals, not fracture outcomes |
| Fracture incidence | The outcome patients care about | Often a secondary safety outcome; observational data are confounded by age, falls, comorbidity and drug choice |
| Falls and physical function | The pathway from weak bone to broken bone | Rarely measured in obesity-drug trials |
What the studies show
| Study / source | Population | Key finding | CEBM |
|---|---|---|---|
| Meta-analysis of 44 RCTs (about 48,000 participants) | Mostly type 2 diabetes | Pooled fracture RR 0.77 (95% CI 0.61–0.96); liraglutide most consistent | 1a |
| Systematic reviews of GLP-1 RAs and BMD | Mostly type 2 diabetes; mixed agents | Small improvements in BMD and turnover markers versus controls | 1a |
| Hansen et al., 2024, 52-week RCT | 64 adults without diabetes at increased fracture risk | Semaglutide: total hip BMD about 2.6% lower than placebo, with higher resorption markers | 1b (small) |
| JAMA Netw Open 2026 (TriNetX, target-trial emulation) | About 66,800 adults with T2D versus DPP-4 inhibitor users; separate non-diabetic comparison | T2D: HR 0.91 (0.88–0.95); no T2D: HR 1.13 (1.04–1.23); protection faded by year 3 and was not explained by weight loss | 2b |
| JAAOS 2026 (Constantine et al.) | 33,210 matched pairs, overweight or obese, no diabetes | One-year fracture incidence 3.05% vs 2.61% (RR 1.09); higher in BMI 40+ (OR 1.26) and ages 78–88 (OR 4.99) | 3 |
| JCEM 2026 matched DXA study | Semaglutide or tirzepatide users at increased fracture risk; median 17 months, median 5% weight loss | Both groups lost hip BMD; without diabetes, annualized total hip loss was about 1% vs 0.6% in controls; weight loss correlated with bone loss | 2b |
| Endocrine Society 2025 abstract (Liu & Walzer) | 255 higher-risk patients, mean age 68, mostly women, about 34 months | With 7% average weight loss: lumbar spine −1.6%, femoral neck −1.8%, total hip −2.8%; 13% had a new fracture | 4 |
| 20-week pilot RCT, post hoc analysis (Frontiers in Aging, 2025) | 20 older adults with overweight or obesity | No clear link between weight lost on semaglutide and BMD or turnover markers (too short and small to settle the question) | 2b (low power) |
Why diabetes and non-diabetes results differ
The most useful insight from the 2026 data is that the same drug class appears to behave differently depending on the patient.
- Type 2 diabetes already weakens bone quality. Fracture risk is higher despite normal or even higher BMD, likely because of glycation, chronic inflammation, microvascular disease and falls from hypoglycemia. Better glucose control with a GLP-1 may reduce some of that burden.
- Without diabetes, there may be less to offset. If a drug has little direct bone benefit, what remains is the effect of weight loss itself: less loading, lean-mass loss and possible nutritional gaps.
- Comparator choice matters. Many diabetes studies compare GLP-1 users with people on DPP-4 inhibitors or sulfonylureas, which are not weight-loss drugs and can carry their own fall or fracture implications. This is not the same as comparing GLP-1 users with people who lost the same weight another way.
The authors of the JAMA Network Open analysis noted that current American Diabetes Association guidance treats GLP-1 effects on BMD as neutral, and suggested that assumption may warrant reevaluation, with baseline bone assessment and monitoring considered during treatment. In our reading, that is a reasonable middle position: not alarm, but not complacency.
Semaglutide and bone
Semaglutide has the most bone-specific data of the two drugs.
- The only randomized body-composition bone trial we identified, a 52-week study in adults without diabetes at higher fracture risk, reported lower hip BMD with semaglutide than placebo, alongside higher bone-resorption markers.
- In the large semaglutide cardiovascular outcomes trial, a safety signal for more hip and pelvic fractures was reported in adults aged 75 and older. It was not a primary endpoint, so it is hypothesis-generating rather than definitive.
- In type 2 diabetes cohorts, semaglutide has been associated with fewer fractures than some comparator drugs. One Stanford analysis presented in 2026 reported about 15% fewer fractures versus dulaglutide and other comparators.
Interpretation: semaglutide may be neutral-to-favorable for fracture in people with diabetes and potentially less favorable for hip BMD in older adults without diabetes, especially when weight loss is substantial.
Tirzepatide and bone
Tirzepatide produces larger average weight loss than semaglutide (for example, 20.2% versus 13.7% in SURMOUNT-5; see our Ozempic vs Wegovy vs Mounjaro vs Zepbound comparison). Because bone loss tends to scale with weight loss, a larger effect would be biologically plausible. The evidence so far is incomplete and conflicting:
- As of October 2026, our literature review did not identify a published randomized trial reporting tirzepatide’s effect on hip or spine BMD.
- A TriNetX cohort of nearly 460,000 adults with type 2 diabetes or obesity reported a higher composite of osteoporosis or fragility fractures with tirzepatide than with other GLP-1 receptor agonists (HR 1.44, 95% CI 1.22–1.69).
- A separate 2026 TriNetX study in older adults with type 2 diabetes (Osteoporosis International) reported lower femoral fracture risk (about 51%) and fewer falls (about 34%) with semaglutide and tirzepatide compared with DPP-4 inhibitors.
- The JCEM 2026 matched DXA study pooled semaglutide and tirzepatide users and did not separate their effects.
- Prospective studies comparing tirzepatide with liraglutide on bone turnover markers are underway.
Interpretation: these results are not contradictory once you consider the comparators. Against DPP-4 inhibitors, tirzepatide looks protective in older diabetic adults; against other GLP-1 drugs, it may look worse, possibly because of greater weight loss, differences in who receives which drug, or residual confounding. No one can currently say tirzepatide is worse than semaglutide for bone, or the reverse.
| Question | Semaglutide | Tirzepatide |
|---|---|---|
| Randomized BMD data in obesity | Yes, one small 52-week trial (lower hip BMD vs placebo) | None identified |
| Fracture signal in T2D | Neutral to lower in cohorts | Lower vs DPP-4i in one cohort; higher vs other GLP-1 RAs in another |
| Fracture signal without T2D | Possible modest increase in older and very-high-BMI groups (class-level data) | Insufficient drug-specific data |
| Average weight loss | Lower | Higher |
| Head-to-head bone trial | None | |
Who is at higher risk
| Group | Why it matters |
|---|---|
| Adults over 65, especially 75+ | Less bone reserve, more falls, and the strongest fracture signals appeared here |
| Postmenopausal women | Accelerated bone loss already under way; weight loss adds to it |
| Prior fragility fracture or known osteopenia/osteoporosis | Highest baseline fracture risk |
| Long-term corticosteroids and other bone-affecting medicines | Additive effects on bone |
| Low muscle mass or frailty | Less skeletal loading and higher fall risk |
| BMI 40 or higher | Largest absolute weight loss, with higher fracture odds in one 2026 analysis |
| Rapid or very large weight loss; poor intake | Bone loss tracks the amount and speed of weight loss |
| Malabsorption, celiac disease, prior bariatric surgery, vitamin D deficiency | Reduced calcium and vitamin D availability |
How to protect your bones on a GLP-1
1. Do progressive resistance and weight-bearing exercise
This is the single best-supported action for both muscle and bone. Aim for resistance training two to three times per week, plus walking or other weight-bearing activity, with load increased gradually. Older adults and anyone with known osteoporosis should get guidance on safe technique, since some spinal flexion movements are not advised. Our muscle-preservation guide covers programming principles.
2. Keep protein adequate
The 2026 joint advisory discussed approximately 1.2–1.6 g/kg/day during active weight reduction, individualized by body size and health status, and lower targets may be needed in kidney disease. Protein supports muscle and the bone matrix.
3. Meet calcium and vitamin D needs
Typical adult recommendations are about 1,000–1,200 mg of total daily calcium (diet plus supplements) and roughly 600–800 IU of vitamin D, with higher needs in some older adults. Food sources come first; supplement to fill gaps rather than assuming more is better. Excess calcium supplements can cause side effects, and vitamin D levels are best guided by a blood test when you are at risk. See our calcium and vitamin D archives.
4. Avoid unnecessarily rapid or extreme weight loss
If appetite is suppressed so much that you cannot eat enough, tell your prescriber. Slower dose escalation, meal planning or a lower maintenance dose may be options. Do not change doses without clinical advice.
5. Prevent falls
Fractures need a fall. Dizziness from dehydration, low blood pressure, low blood sugar (especially with insulin or sulfonylureas) and muscle weakness all raise risk. Review medications, home hazards and balance training with your clinician.
6. Review other bone-affecting factors
Smoking, heavy alcohol use, long-term steroids, proton pump inhibitors, thyroid disease and sex-hormone deficiency can all affect bone and are worth reviewing during a weight-loss program.
When to get a DXA scan
There is no universal rule for scanning every GLP-1 user, but a baseline DXA is reasonable if you already meet standard screening criteria or have additional risk factors:
- Women aged 65 or older, and postmenopausal women under 65 with risk factors
- Men aged 70 or older, and younger men with major risk factors
- Prior fragility fracture, long-term steroid use, early menopause, family history of hip fracture
- Other conditions that affect bone, such as hyperparathyroidism, malabsorption or hypogonadism
Practical points: use the same machine for follow-up scans, ask for hip and spine results, and interpret small changes cautiously because ordinary measurement error can be around 1–2% or more. A repeat scan is often considered after one to two years of treatment in higher-risk people. Your clinician may also use a fracture risk calculator such as FRAX to guide treatment decisions.
What about stopping the drug?
Long-term data on bone after stopping are scarce. Weight regain does not reliably restore bone that was lost, so the practical goal is to protect bone during treatment and plan for a maintenance strategy. For the broader picture, see what happens when you stop GLP-1. Do not stop a prescribed medicine solely because of this article; weigh the benefits of weight loss on cardiovascular, metabolic and joint health against individual bone risk with your clinician.
Evidence grading (CEBM)
| Claim | CEBM level | Confidence and note |
|---|---|---|
| Weight loss from any cause lowers hip BMD | 1a | High; well established outside GLP-1 research |
| Semaglutide or tirzepatide use is associated with hip BMD decline that tracks weight loss | 1b–2b | Moderate; small RCT plus matched cohorts |
| GLP-1 RAs lower fracture risk in type 2 diabetes | 1a–2b | Moderate; fractures often secondary outcomes, comparators vary, benefit may fade over time |
| GLP-1 RAs modestly raise fracture risk in non-diabetic obesity | 2b–3 | Low; observational, confounded, concentrated in specific subgroups |
| Tirzepatide is worse (or better) for bone than semaglutide | 2b | Very low; conflicting cohorts, no randomized data |
| Resistance and weight-bearing exercise helps preserve bone during weight loss | 1a (weight-loss literature) | Moderate to high; not tested specifically in large GLP-1 outcome trials |
| Adequate protein, calcium and vitamin D support bone | 1a–2a | Moderate; benefit greatest when intake was previously inadequate |
Frequently asked questions
Do semaglutide and tirzepatide cause bone loss?
Weight loss from these medicines is associated with measurable declines in hip and spine bone mineral density in several studies, particularly in people without diabetes and in older adults. This appears to be driven largely by the amount of weight lost rather than proven direct bone toxicity. Whether it raises fracture risk is still uncertain and varies by population.
Do GLP-1 drugs increase fracture risk?
Results are mixed. In type 2 diabetes, trial meta-analyses and large cohort studies suggest similar or lower fracture risk. In people with obesity without diabetes, some 2026 cohort data suggest a modest increase, concentrated in people aged roughly 78 to 88 and those with BMI 40 or higher. These are observational findings and do not prove causation.
Is tirzepatide worse for bones than semaglutide?
This is not established. One large real-world cohort reported a higher composite of osteoporosis or fragility fractures with tirzepatide than with other GLP-1 receptor agonists, while another 2026 cohort found lower femoral fracture and fall risk with semaglutide and tirzepatide than with DPP-4 inhibitors in older adults with type 2 diabetes. No head-to-head randomized bone-density trial exists.
Should I get a DXA bone density scan before starting a GLP-1?
A baseline DXA is reasonable if you already meet standard screening criteria, such as being a woman aged 65 or older, a postmenopausal woman at higher risk, a man aged 70 or older, or having prior fragility fracture, long-term steroid use, or other major risk factors. Discuss timing with your clinician, since a scan may also help interpret later changes.
How can I protect my bones while losing weight on a GLP-1?
The best-supported steps are progressive resistance and weight-bearing exercise, adequate protein, adequate calcium and vitamin D, avoiding unnecessarily rapid or extreme weight loss, fall prevention, and review of other bone-affecting medicines with your clinician.
Do I need calcium and vitamin D supplements on a GLP-1?
Not everyone does. The goal is to meet usual daily calcium and vitamin D needs from food first and to supplement only to fill gaps, ideally guided by your diet, risk factors and, when appropriate, a vitamin D blood test. Reduced appetite can make it harder to reach these targets.
Does bone density recover after stopping a GLP-1?
Long-term data on recovery are limited. Bone changes after weight loss are generally slower to reverse than the weight itself, and regaining weight does not reliably restore bone quality. Exercise, nutrition and clinical follow-up remain the main tools.
Who should be most careful about bone health on semaglutide or tirzepatide?
Older adults, postmenopausal women, people with prior fragility fractures or known osteoporosis, long-term corticosteroid users, people with low muscle mass or poor nutrition, people with very high BMI, and anyone losing weight rapidly deserve closer attention and an individualized bone-health plan.
AI personalization guide: use AI assistants to prepare for your bone-health conversation
AI assistants can help you organize questions and understand a DXA report, but they cannot diagnose you or choose treatment. Remove your name and identifiers before pasting medical information. Use the prompts below as starting points.
| Assistant | Best use | Example prompt |
|---|---|---|
| Claude | Explaining a DXA report in plain language and drafting questions for your doctor | “Here is my DXA report (identifiers removed). Explain the T-scores and Z-scores, what the hip and spine numbers mean, and list questions to ask my clinician about continuing semaglutide.” |
| ChatGPT | Building a personalized exercise and meal-planning checklist to discuss with a professional | “I am [age/sex], on tirzepatide, and want to protect bone density. Create a weekly strength and weight-bearing plan and a calcium and protein food checklist I can review with my doctor.” |
| Gemini | Pulling together recent news and linking to sources you can open | “Summarize 2026 research on GLP-1 drugs and fracture risk, and give me links to the original studies so I can read the abstracts.” |
| Perplexity | Citation-first literature searches | “What randomized trials report bone mineral density with semaglutide or tirzepatide in adults without diabetes? List study type, sample size and result for each, with citations.” |
Tips for better answers: state your age, sex, menopause status, weight change, current medicines and any prior fractures; ask the assistant to separate randomized trials from observational studies; ask it to say what is uncertain; and always verify claims against the original papers. If an AI answer conflicts with your clinician, trust your clinician and ask them to explain.
Bottom line
Semaglutide and tirzepatide are not known to weaken bone on their own, but substantial weight loss on either is associated with lower hip and spine BMD, and the fracture picture is genuinely mixed. People with type 2 diabetes may see neutral or even favorable fracture outcomes, while older adults and people with very high BMI who do not have diabetes deserve the closest attention. Tirzepatide-specific bone data remain thin.
For most people, the practical answer is not to avoid effective treatment but to treat bone health as part of the plan: strength and weight-bearing exercise, enough protein, calcium and vitamin D, steady weight loss, fall prevention, and a DXA scan if you meet screening criteria.
Related GLP-1 guides
- Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?
- How to Prevent Muscle Loss on GLP-1 Drugs
- GLP-1 Nutrient Deficiency Protocol 2026
- GLP-1 Side Effects and Safety
- What Happens When You Stop GLP-1
- GLP-1 Manual 2026: The Complete Guide
Knowledge graph: GLP-1 & Peptide Hub → Starting GLP-1 → muscle loss → bone density → nutrient monitoring → stopping GLP-1.
References and primary sources
- Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes. JAMA Network Open. 2026;9(7):e2625141. doi:10.1001/jamanetworkopen.2026.25141. Summaries: Epocrates; Drug Topics.
- Constantine E, Enthoven L, Kahan R, Pflug E, Lauder A. The impact of glucagon-like peptide-1 receptor agonists on fracture risk in overweight or obese, nondiabetic patients. J Am Acad Orthop Surg. 2026;34(12):e1610–e1619. doi:10.5435/JAAOS-D-24-01505. Interview summary: AAOS Now, September 2026.
- Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures. J Clin Endocrinol Metab. 2026. Abstract record.
- Liu Y, Walzer D. Semaglutide and tirzepatide, bone mineral density and fracture incidence (abstract). J Endocr Soc. 2025;9(Suppl 1):bvaf149.558. Abstract. Overview: Drug Topics, July 2026.
- Hansen MS, et al. Semaglutide and bone density at 52 weeks in adults without diabetes at increased fracture risk, 2024. Summarized at The RX Index. Verify against the original publication before citing clinically.
- Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: a retrospective cohort study using the TriNetX database. Summary: Medical Dialogues.
- Chen, Wu, Chu, et al. Semaglutide and tirzepatide versus DPP-4 inhibitors and femoral fracture and fall risk in older adults with type 2 diabetes. Osteoporos Int. 2026. PMID 42435064. Summary.
- Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis. Front Aging. 2025. doi:10.3389/fragi.2025.1691007.
- Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2025;62(5):589–606. doi:10.1007/s00592-025-02468-5.
- Zhang Y, et al. Association of GLP-1 receptor agonists use with fracture risk in type 2 diabetes: a meta-analysis of randomized controlled trials. Bone. 2025;192:117338. doi:10.1016/j.bone.2024.117338.
- Cheng L, et al. GLP-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2019;35:e3168. doi:10.1002/dmrr.3168.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393:26–36. doi:10.1056/NEJMoa2416394. PubMed.
- Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society. PMC full text.
- Weight-loss-dependent changes in body composition and bone health in people with obesity and type 1 diabetes treated with liraglutide, semaglutide or tirzepatide. University of Glasgow repository. Record.
.png)
.png)
Comments